Labiotech.eu

More News! 6 Apr 2017

Fear & Loathing in GMOs: How do you change concerned minds?

The house was packed to hear Joyce Tait of the Innogen Institute and Mark Lynas, an environmental writer, speak about smarter approaches to GM regulations. The second day of SynBioBeta yesterday started early, but fuelled by a passion for synthetic biology (on which a number of speakers commented), attendees packed into the lecture hall for a fireside chat on GMO regulation with Joyce […]

April 6, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 6 Apr 2017

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

How is Biotech Transforming Pharma’s R&D Model?

Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […]

April 6, 2017 - 4 minutesmins - By External Contributor

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […]

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

Infographics 5 Apr 2017

Infographic: Europe’s Best Biotechs Mining the Microbiome

We gathered the best of the best companies in Europe working on therapies from the microbiome — here are the names you should know! Justine Braguy is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf and KAUST in Saudi Arabia after obtaining a Masters in Biotechnology at Ecole Supérieure de Biotechnologie de Strasbourg (ESBS). In her spare […]

April 5, 2017 - 1 minutemin - By External Contributor

News and Trends 5 Apr 2017

Planning a Clinical Trial – Think Smart Design

By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products. “Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol once the study has been initiated. The use of interim analyses, and in particularly the development of […]

April 5, 2017 - 5 minutesmins - By External Contributor

More News! 4 Apr 2017

SynBioBeta Launches Venture Fund for Synthetic Biology Startups

US-based venture capital fund Data Collective has announced that it is partnering with SynBioBeta to launch a new synthetic biology venture fund. Data Collective will join forces with SynBioBeta founder John Cumbers to launch the DCVC SynBioBeta fund, a pre-seed and seed VC fund to invest in synthetic biology startups. John Cumbers, an expert on […]

April 4, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 4 Apr 2017

Sample a More Efficient Sorbent to Streamline your mAb Purification

Need an efficient way to purify your antibodies but struggle to find the best column? Pall Life Sciences is giving you the opportunity to try their solution for free. Enter your email below and receive your KANEKA Protein A sorbent sample! Pall Life Sciences is giving you a chance to try for free the new, […]

April 4, 2017 - 2 minutesmins - By External Contributor

young researchers entrepreneurs biotech europe 1

Best in Biotech 4 Apr 2017

Top Young Researchers Making Names for Themselves in Industry

How long do you have to invest in academia before you can found a biotech company? Not as long as you might think, even for those going up the academic ladder. After profiling some of the biotech researchers that are most active in entrepreneurship and 10 impressive founders under 30, we have asked around for a combination of […]

April 4, 2017 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 3 Apr 2017

Massive €800M Acquisition of Belgian Biotech treating Menopause

Astellas Pharma is acquiring Ogeda, getting hold of its promising Phase II candidate to treat menopause without hormonal therapy. After acquiring Ganymed Pharmaceuticals last October for a record €1.3B in German biotech, the Japanese Astellas Pharma is making a second massive acquisition in Europe. Its new addition is Ogeda, a Belgian biotech targeting GPCRs to treat gynecological […]

April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 3 Apr 2017

First Treatment for Severe Premenstrual Syndrome Clears Phase II

Swedish Asarina Pharma has announced positive results of a Phase IIa study for the treatment of Premenstrual Dysphoric Disorder (PMDD). With only a single product candidate in its pipeline, Asarina Pharma is focusing on the development of the first potential therapy for the treatment of PMDD, a severe and disabling form of premenstrual syndrome that affects about 5% of […]

April 3, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Fear & Loathing in GMOs: How do you change concerned minds?

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

How is Biotech Transforming Pharma’s R&D Model?

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Infographic: Europe’s Best Biotechs Mining the Microbiome

Planning a Clinical Trial – Think Smart Design

SynBioBeta Launches Venture Fund for Synthetic Biology Startups

Sample a More Efficient Sorbent to Streamline your mAb Purification

Top Young Researchers Making Names for Themselves in Industry

Massive €800M Acquisition of Belgian Biotech treating Menopause

First Treatment for Severe Premenstrual Syndrome Clears Phase II

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!